en · de · es
faq-desk.peptides5388.com › Info › Identity And Molecular Context — Research Overview

Identity And Molecular Context — Research Overview

By Editorial Desk · published 2026-05-14 · last reviewed 2026-07-04 · Info

hGH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2026-07-04. Numbers and descriptions here follow the published literature rather than marketing material.

Identity and Molecular Context

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.

The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.

Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.

Mechanism and Regulatory Status

Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.

Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.

Aod-9604 at a glance

PropertyValueNotes
Molecular classSynthetic peptideDerived from a fragment of human growth hormone
Sequence basishGH residues 176-191Commonly described as a 16-amino-acid fragment
AppearanceWhite to off-white powderTypical for lyophilized research peptides
SolubilitySoluble in water or aqueous bufferExact solubility depends on pH and purity
Common synonymsAOD9604; hGH 176-191Spelling and punctuation vary across sources

Research and Regulatory Context

AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.

Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.

Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.

Related pages on this site

Measurement and Storage Practices

Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.

Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.

Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.

Background and Development History

AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.

Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.

Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.

Reference notes

=== Further synthesis methods === Pyridines can also be prepared via a Mannich reaction. The products are β-aminoketones (Mannich bases). If the hydrochloride of such a base is reacted with an aldehyde and ammonium acetate, a correspondingly substituted pyridine is obtained. In the Bohlmann-Rahtz synthesis, an enamine is first added to an alkynone. A pyridine is then formed by intramolecular condensation reaction and dehydration between the ketone and the amino group. Under suitable conditions, the enamino ester can be generated in situ. For this purpose, the alkynone can be reacted with ammonium acetate, a keto ester, and an acidic catalyst such as acetic acid or zinc bromide.

However, after that there was no mention of Jerry whatsoever, and it became apparent that the character—along with much of seasons 6 through 9 -- was simply retconned out of existence. In The Conners, various characters mentioned that there are only three Conner children.

== Function == CART is a neuropeptide that produces similar behavior in animals as cocaine and amphetamine, but conversely blocks the effects of cocaine when they are co-administered. The peptide is found in several areas, among them the ventral tegmental area (VTA) of the brain. When CART was injected into rat VTA, increased locomotor activity was seen, which is one of the signs of "central stimulation" caused by psychostimulants, such as cocaine and amphetamine. The same rats also tended to return to the place where they were injected. This is called conditioned place preference and is also seen after injection of cocaine. CART peptides, in particular, CART(55–102), seem to have an important function in the regulation of energy homeostasis and interact with several hypothalamic appetite circuits. CART expression is regulated by several peripheral peptide hormones involved in appetite regulation, including leptin, cholecystokinin and ghrelin, with CART and cholecystokinin having synergistic effects on appetite regulation. CART is released in response to repeated dopamine release in the nucleus accumbens, and may regulate the activity of neurons in this area. CART production is upregulated by CREB, a protein thought to be involved with the development of drug addiction, and CART may be an important therapeutic target in the treatment of stimulant abuse.

==== Elimination ==== Muscimol is excreted by the kidneys into urine. It is excreted partially unmetabolized. This has been taken advantage of by Siberian practitioners of the traditional entheogenic use of Amanita muscaria via recycling of muscimol in urine. The elimination half-life of muscimol in humans is unknown. The closely related drug gaboxadol (THIP), which is a cyclized derivative of muscimol, has an elimination half-life in humans of 1.5 to 2 hours. In rodents, the half-life of gaboxadol was about twice as long as that of muscimol. Gaboxadol is said to be more resistant to metabolism than muscimol, for instance not being a substrate for GABA-T. Despite the preceding findings however, gaboxadol is shorter-lasting in its effects than muscimol in rats, with durations of up to 3 hours and more than 5 hours, respectively.

Sources: en.wikipedia.org

Notes from published material

== History and development == The first site was launched in 2001 by the American Association for Clinical Chemistry, the scientific society for clinical laboratory science. This led to a collaboration with professional societies in 17 other countries representing the laboratory medicine community. Each site is separately managed to allow both appropriate languages and information that matches local needs.

==== Using a tincture ==== Less commonly, some may ingest salvia in the form of a tincture. This is administered sublingually, usually with the aid of a glass dropper. It may be taken diluted with water just before use, which may slightly reduce the intensity of its effects, but can also serve to lessen or avoid a stinging sensation in the mouth caused by the presence of alcohol. Tinctures vary in potency, and the effects can range from inducing a mild meditative state to bringing about a more intense hallucinatory one. When taken as a tincture the effects and duration are similar to other methods of oral ingestion, though they may be significantly more intense, depending on extract potency.

=== Long fiber generation === In 2013, a group from the University of Tokyo developed cell laden fibers up to a meter in length and on the order of 100 μm in size. These fibers were created using a microfluidic device that forms a double coaxial laminar flow. Each 'layer' of the microfluidic device (cells seeded in ECM, a hydrogel sheath, and finally a calcium chloride solution). The seeded cells culture within the hydrogel sheath for several days, and then the sheath is removed with viable cell fibers. Various cell types were inserted into the ECM core, including myocytes, endothelial cells, nerve cell fibers, and epithelial cell fibers. This group then showed that these fibers can be woven together to fabricate tissues or organs in a mechanism similar to textile weaving. Fibrous morphologies are advantageous in that they provide an alternative to traditional scaffold design, and many organs (such as muscle) are composed of fibrous cells.

Sources: en.wikipedia.org

Further detail

Microplastic is a type of airborne particulates and is found to prevail in air. A 2017 study found indoor airborne microfiber concentrations between 1.0 and 60.0 microfibers per cubic meter (33% of which were found to be microplastics). Airborne microplastic dust can be produced during renovation, building, bridge and road reconstruction projects and the use of power tools.

Louis Klarevas, a professor at New York University's Center for Global Affairs, said of the products on the list of potentially harmful products reaching the US in recent years were exclusive to China: "Yet as more large-scale labor markets compete for their share of international trade, the incentives to cut corners will increase and the temptation to overlook hazardous goods might become a more common occurrence." On 10 November 2008 issue of the Singaporean newspaper Today, Bill Durodié, then a senior fellow at the S. Rajaratnam School of International Studies responded to the possibility of more such incidents in the future due to the more liberal trading relations with China by saying: "exposing the Chinese to the world market is probably the fastest way of addressing these issues."

Helton enjoyed arguably his best season in 2000, leading the major leagues in batting average (.372), RBI (147), doubles (59), total bases (405), extra base hits (103), slugging percentage (.698) and OPS (1.162). He led the NL in hits (216) and on-base percentage (.463). Helton hit a league-leading home batting average of .391 and was third in the NL in road batting average (.353). Helton's MLB-leading 103 extra base hits tied for the fourth most in MLB history and the second most in NL history. His league-leading numbers in on-base percentage, slugging percentage and batting average gave him the "percentage triple crown." Helton became the second Rockies player, after Larry Walker in 1999, to accomplish that feat. Helton and Walker made the Rockies the first team in MLB history to record percentage triple crowns in consecutive seasons with different players. Helton became only the fourth player in NL history to lead the league in both batting average and RBI. He became the first player in NL history and the fifth player in MLB history (Babe Ruth, Lou Gehrig, Jimmie Foxx and Hank Greenberg are the others) to have at least 200 hits, 40 home runs, 100 RBI, 100 runs, 100 extra base hits, and 100 walks in one season. Helton was invited to his first career MLB All-Star Game in 2000. He also received NL Player of the Month honors for May and August. He finished fifth in voting for the MVP award. However, the Associated Press, Sporting News, USA Baseball Alumni, and Baseball Digest all named Helton the MLB Player of the Year.

By July, the Centre was the only non-Nazi party that still even nominally existed; the SPD and KPD had been banned outright, while the others had been browbeaten into dissolving themselves. On 1 July, Papen and Kaas agreed that as part of the concordat, German priests would stay out of politics. As it turned out, the party dissolved on 5 July—much to the dismay of Cardinal Pacelli, who felt the party should at least have waited until after the conclusion of negotiations. The day after, the government issued a law outlawing the formation of new political parties, thereby making the NSDAP the only legally permitted party in Germany.

Sources: en.wikipedia.org

Frequently asked questions

Is AOD-9604 the same as human growth hormone?

No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.

What is the exact length of AOD-9604?

It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.

Does AOD-9604 occur naturally?

It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.

Is AOD-9604 approved for weight loss?

No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.

Network